These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38091052)

  • 21. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
    Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
    Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 'MACHO' chemotherapy for stage IV B cell lymphoma and B cell acute lymphoblastic leukaemia of childhood. United Kingdom Children's Cancer Study Group (UKCCSG).
    Hann IM; Eden OB; Barnes J; Pinkerton CR
    Br J Haematol; 1990 Nov; 76(3):359-64. PubMed ID: 2261346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of Central Nervous System (CNS) Involvement in Children With Non-Hodgkin's Lymphoma (NHL) and the Diagnostic Value of CSF Flow Cytometry in CNS Positive Disease.
    Huang S; Jin L; Yang J; Duan Y; Zhang M; Zhou C; Zhang YH
    Technol Cancer Res Treat; 2021; 20():15330338211016372. PubMed ID: 34060372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
    Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
    Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapy for Burkitt's lymphoma according to the BL-M-04 protocol: 12-year experience].
    Baryakh EA; Tyurina NG; Vorobyev VI; Gemdzhyan EG; Mangasarova YK; Klyasova GA; Kovrigina AM; Obukhova TN; Zvonkov EE; Vernyuk MA; Chervontseva AM; Polyakov YY; Misyurina АЕ; Valiev TT; Zherebtsova VA; Magomedova AU; Galstyan GM; Yatskov KV; Nesterova ES; Vorobyev AI; Kravchenko SK
    Ter Arkh; 2015; 87(7):4-14. PubMed ID: 26390720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long term efficacy of COPADM regimen in the treatment of 20 patients with Burkitt lymphoma].
    Yang D; Wang P; Chen J; Li CX; Zhang Y; Chen XC; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):645-649. PubMed ID: 30180465
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical Characteristics and Outcomes of AIDS-Related Burkitt Lymphoma in China: A Retrospective Single-Center Study.
    Liu R; Zhao H; Xiao G; Tao Y; Tang X; Feng L; Liao B; Liu B; Guan J; Li L; Chen Z; He H; You H
    Technol Cancer Res Treat; 2024; 23():15330338231214236. PubMed ID: 38179657
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical characteristics and outcomes of newly diagnosed patients with HIV-associated aggressive B-cell NHL in China.
    Wang C; Liu J; Lei H; Li Y; Wu J; Guo B; Hu R; Liu T; Wu J; Ding Y; Hu C; Liang S; Xiao C; Liang X; Huang D; Yang T; Zhang W; Yang Z; Li J; Nan Y; Li Q; Xiang Y; Li Z; Wu Y; Liu Y
    J Cell Mol Med; 2022 Oct; 26(19):5067-5077. PubMed ID: 36056692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
    Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Long-term clinical outcome of children and adolescents with Burkitt's lymphoma treated with rituximab combined with modified NHL-BFM-90 regimen].
    Li YX; Yin QS; Ai H; Mi RH; Zhang LN; Li YF; Wei XD; Song YP
    Zhonghua Yi Xue Za Zhi; 2019 Feb; 99(8):605-610. PubMed ID: 30818930
    [No Abstract]   [Full Text] [Related]  

  • 32. [A collaborative study on children with mature B-cell non-Hodgkin's lymphoma in China].
    ; ; ;
    Zhonghua Er Ke Za Zhi; 2014 Sep; 52(9):649-54. PubMed ID: 25476425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.
    Sýkorová A; Procházka V; Móciková H; Janíková A; Pytlík R; Belada D; Benešová K; Klener P; Ďuraš J; Smolej L; Campr V; Blahovcová P; Trněný M
    Neoplasma; 2022 Dec; 69(6):1466-1473. PubMed ID: 36591807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.
    Patte C; Auperin A; Gerrard M; Michon J; Pinkerton R; Sposto R; Weston C; Raphael M; Perkins SL; McCarthy K; Cairo MS;
    Blood; 2007 Apr; 109(7):2773-80. PubMed ID: 17132719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical features and prognosis of children with mature B-cell non-Hodgkin's lymphoma: an analysis of 28 cases].
    Chen ZS; Zheng YZ; Chen YQ; Gao QL; Li J; Shen JZ
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jun; 20(6):470-474. PubMed ID: 29972121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.
    Poirel HA; Cairo MS; Heerema NA; Swansbury J; Aupérin A; Launay E; Sanger WG; Talley P; Perkins SL; Raphaël M; McCarthy K; Sposto R; Gerrard M; Bernheim A; Patte C;
    Leukemia; 2009 Feb; 23(2):323-31. PubMed ID: 19020548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical analysis of a modified LMB89 Group C regimen in the treatment of pediatric high-risk Burkitt lymphoma].
    Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):633-638. PubMed ID: 31495128
    [No Abstract]   [Full Text] [Related]  

  • 38. [The clinical characteristics and outcomes of 16 Burkitt' s lymphoma with testicular involvement].
    Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Zhang YH
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):768-773. PubMed ID: 27719719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine.
    Murphy SB; Bowman WP; Abromowitch M; Mirro J; Ochs J; Rivera G; Pui CH; Fairclough D; Berard CW
    J Clin Oncol; 1986 Dec; 4(12):1732-9. PubMed ID: 3491184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country.
    Ahmad N; Zaidi A; Badar F; Maaz AU; Akram MS
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):49-56. PubMed ID: 20398038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.